SNYNF News Alert Sanofi-Aventis Sa (SNYNF) 98.2500 02/15/2015
Post# of 64074
Posted On: 02/15/2015 2:37:44 PM
Sanofi-Aventis Sa (SNYNF) 98.2500 $SNYNF
Update: Sanofi Will Hire A New CEO Shortly, But Growth Remains Muted
Early Retiree - at Seeking Alpha - Thu Feb 05, 3:30AM CST
SNY: 49.42 (+0.82)
MannKind earns milestone
Seeking Alpha - at Seeking Alpha - Thu Jan 08, 7:08AM CST
SNY: 49.42 (+0.82), MNKD: 7.00 (+0.02)
FDA clears Sanofi's four-strain flu vaccine
Seeking Alpha - at Seeking Alpha - Fri Dec 12, 9:26AM CST
SNY: 49.42 (+0.82)
Disgruntled ex-employee says Sanofi paid kickbacks to boost drug sales
Seeking Alpha - at Seeking Alpha - Fri Dec 05, 7:12AM CST
SNY: 49.42 (+0.82)
FDA approves expanded label for Sanofi TB med
Seeking Alpha - at Seeking Alpha - Tue Dec 02, 8:32AM CST
SNY: 49.42 (+0.82)
Sanofi backs out of commercialization deal with Pozen
Seeking Alpha - at Seeking Alpha - Mon Dec 01, 6:41AM CST
POZN: 6.95 (+0.15), SNY: 49.42 (+0.82)
Europe Ad Comm recommends approval of Celgene's Otezla
Seeking Alpha - at Seeking Alpha - Fri Nov 21, 7:04AM CST
SHPG: 239.82 (+6.11), PFE: 34.64 (-0.23), PLX: 1.84 (-0.04), SNY: 49.42 (+0.82), CELG: 115.88 (+0.16)
Europe Ad Comm supports approval of Genzyme Gaucher drug
Seeking Alpha - at Seeking Alpha - Fri Nov 21, 6:38AM CST
SHPG: 239.82 (+6.11), PFE: 34.64 (-0.23), PLX: 1.84 (-0.04), SNY: 49.42 (+0.82)
Dupilumab tagged a Breakthrough Therapy for atopic dermatitis
Seeking Alpha - at Seeking Alpha - Thu Nov 20, 7:16AM CST
SNY: 49.42 (+0.82), REGN: 402.40 (+0.66)
Positive clinical trial results for alirocumab presented at AHA meeting
Seeking Alpha - at Seeking Alpha - Wed Nov 19, 11:35AM CST
AMGN: 153.48 (+0.30), SNY: 49.42 (+0.82), REGN: 402.40 (+0.66)
Genzyme and Isis Pharma announce presentation on cardiac benefits of Kynamro
Seeking Alpha - at Seeking Alpha - Tue Nov 18, 3:37PM CST
ISIS: 63.86 (-0.43), SNY: 49.42 (+0.82)
Eylea expands label in Japan
Seeking Alpha - at Seeking Alpha - Tue Nov 18, 8:32AM CST
SNY: 49.42 (+0.82), REGN: 402.40 (+0.66)
Sanofi/Regeneron asthma drug successful in Phase 2 trial
Seeking Alpha - at Seeking Alpha - Tue Nov 11, 6:44AM CST
MRK: 58.81 (-0.07), AZN: 69.96 (+0.20), AMGN: 153.48 (+0.30), TEVA: 56.77 (-0.58), THRX: 14.85 (+1.00), GSK: 47.94 (+1.99), SNY: 49.42 (+0.82), REGN: 402.40 (+0.66), NVS: 102.20 (-0.17)
Update: Sanofi Destroys Shareholder Value
Early Retiree - Seeking Alpha - Thu Oct 30, 8:56AM CDT
After downplaying the rumors yesterday, this morning the BOD of Sanofi removed the CEO . This is bad news for shareholders, and will certainly mark the start of a not very cooperative transition period. The background for the decision could easily...
SNY: 49.42 (+0.82)
Update: Sanofi Will Deliver Growth, But Later Than Expected
Early Retiree - at Seeking Alpha - Wed Oct 29, 9:46AM CDT
SNY: 49.42 (+0.82)
Sanofi Q3 net income up 8%
Seeking Alpha - at Seeking Alpha - Tue Oct 28, 8:14AM CDT
SNY: 49.42 (+0.82)
Sanofi off premarket on soft diabetes forecast
Seeking Alpha - at Seeking Alpha - Tue Oct 28, 6:31AM CDT
NVO: 43.76 (+0.61), SNY: 49.42 (+0.82)
BI begins enrollment in Phase 3 CRC trial
Seeking Alpha - at Seeking Alpha - Tue Oct 21, 8:08AM CDT
MGNX: 34.09 (+0.10), IMMU: 3.84 (unch), ONCY: 0.51 (+0.02), ARQL: 1.35 (+0.04), AMGN: 153.48 (+0.30), LLY: 70.56 (+0.03), BMY: 60.04 (+0.56), GILD: 101.90 (+1.10), SNY: 49.42 (+0.82), REGN: 402.40 (+0.66)
Dupilumab dermatitis trial underway
Seeking Alpha - at Seeking Alpha - Mon Oct 20, 7:56AM CDT
PRGO: 150.90 (+0.22), VRX: 167.00 (-0.50), ANAC: 40.76 (-0.07), GSK: 47.94 (+1.99), SNY: 49.42 (+0.82), REGN: 402.40 (+0.66)
Amgen sues Sanofi and Regeneron
Seeking Alpha - at Seeking Alpha - Fri Oct 17, 8:30AM CDT
AMGN: 153.48 (+0.30), SNY: 49.42 (+0.82), REGN: 402.40 (+0.66)
Update: Sanofi Will Hire A New CEO Shortly, But Growth Remains Muted
Early Retiree - at Seeking Alpha - Thu Feb 05, 3:30AM CST
SNY: 49.42 (+0.82)
MannKind earns milestone
Seeking Alpha - at Seeking Alpha - Thu Jan 08, 7:08AM CST
SNY: 49.42 (+0.82), MNKD: 7.00 (+0.02)
FDA clears Sanofi's four-strain flu vaccine
Seeking Alpha - at Seeking Alpha - Fri Dec 12, 9:26AM CST
SNY: 49.42 (+0.82)
Disgruntled ex-employee says Sanofi paid kickbacks to boost drug sales
Seeking Alpha - at Seeking Alpha - Fri Dec 05, 7:12AM CST
SNY: 49.42 (+0.82)
FDA approves expanded label for Sanofi TB med
Seeking Alpha - at Seeking Alpha - Tue Dec 02, 8:32AM CST
SNY: 49.42 (+0.82)
Sanofi backs out of commercialization deal with Pozen
Seeking Alpha - at Seeking Alpha - Mon Dec 01, 6:41AM CST
POZN: 6.95 (+0.15), SNY: 49.42 (+0.82)
Europe Ad Comm recommends approval of Celgene's Otezla
Seeking Alpha - at Seeking Alpha - Fri Nov 21, 7:04AM CST
SHPG: 239.82 (+6.11), PFE: 34.64 (-0.23), PLX: 1.84 (-0.04), SNY: 49.42 (+0.82), CELG: 115.88 (+0.16)
Europe Ad Comm supports approval of Genzyme Gaucher drug
Seeking Alpha - at Seeking Alpha - Fri Nov 21, 6:38AM CST
SHPG: 239.82 (+6.11), PFE: 34.64 (-0.23), PLX: 1.84 (-0.04), SNY: 49.42 (+0.82)
Dupilumab tagged a Breakthrough Therapy for atopic dermatitis
Seeking Alpha - at Seeking Alpha - Thu Nov 20, 7:16AM CST
SNY: 49.42 (+0.82), REGN: 402.40 (+0.66)
Positive clinical trial results for alirocumab presented at AHA meeting
Seeking Alpha - at Seeking Alpha - Wed Nov 19, 11:35AM CST
AMGN: 153.48 (+0.30), SNY: 49.42 (+0.82), REGN: 402.40 (+0.66)
Genzyme and Isis Pharma announce presentation on cardiac benefits of Kynamro
Seeking Alpha - at Seeking Alpha - Tue Nov 18, 3:37PM CST
ISIS: 63.86 (-0.43), SNY: 49.42 (+0.82)
Eylea expands label in Japan
Seeking Alpha - at Seeking Alpha - Tue Nov 18, 8:32AM CST
SNY: 49.42 (+0.82), REGN: 402.40 (+0.66)
Sanofi/Regeneron asthma drug successful in Phase 2 trial
Seeking Alpha - at Seeking Alpha - Tue Nov 11, 6:44AM CST
MRK: 58.81 (-0.07), AZN: 69.96 (+0.20), AMGN: 153.48 (+0.30), TEVA: 56.77 (-0.58), THRX: 14.85 (+1.00), GSK: 47.94 (+1.99), SNY: 49.42 (+0.82), REGN: 402.40 (+0.66), NVS: 102.20 (-0.17)
Update: Sanofi Destroys Shareholder Value
Early Retiree - Seeking Alpha - Thu Oct 30, 8:56AM CDT
After downplaying the rumors yesterday, this morning the BOD of Sanofi removed the CEO . This is bad news for shareholders, and will certainly mark the start of a not very cooperative transition period. The background for the decision could easily...
SNY: 49.42 (+0.82)
Update: Sanofi Will Deliver Growth, But Later Than Expected
Early Retiree - at Seeking Alpha - Wed Oct 29, 9:46AM CDT
SNY: 49.42 (+0.82)
Sanofi Q3 net income up 8%
Seeking Alpha - at Seeking Alpha - Tue Oct 28, 8:14AM CDT
SNY: 49.42 (+0.82)
Sanofi off premarket on soft diabetes forecast
Seeking Alpha - at Seeking Alpha - Tue Oct 28, 6:31AM CDT
NVO: 43.76 (+0.61), SNY: 49.42 (+0.82)
BI begins enrollment in Phase 3 CRC trial
Seeking Alpha - at Seeking Alpha - Tue Oct 21, 8:08AM CDT
MGNX: 34.09 (+0.10), IMMU: 3.84 (unch), ONCY: 0.51 (+0.02), ARQL: 1.35 (+0.04), AMGN: 153.48 (+0.30), LLY: 70.56 (+0.03), BMY: 60.04 (+0.56), GILD: 101.90 (+1.10), SNY: 49.42 (+0.82), REGN: 402.40 (+0.66)
Dupilumab dermatitis trial underway
Seeking Alpha - at Seeking Alpha - Mon Oct 20, 7:56AM CDT
PRGO: 150.90 (+0.22), VRX: 167.00 (-0.50), ANAC: 40.76 (-0.07), GSK: 47.94 (+1.99), SNY: 49.42 (+0.82), REGN: 402.40 (+0.66)
Amgen sues Sanofi and Regeneron
Seeking Alpha - at Seeking Alpha - Fri Oct 17, 8:30AM CDT
AMGN: 153.48 (+0.30), SNY: 49.42 (+0.82), REGN: 402.40 (+0.66)
(0)
(0)Scroll down for more posts ▼